---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058156"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:46:49.773729+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Syndax reports Q3 net loss $0.73/sh, initiates revumenib NDA in R/R KMT2Ar leukemia

## Summary
- Net loss $51.1M ($0.73/sh) vs $35.4M ($0.58/sh) YoY; cash $379.3M as of Sep 30, 2023.
- NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under FDA RTOR; completion expected by year-end 2023.
- Final Phase 1 mNPM1 data: 36% CR/CRh (5/14); 100% of CR/CRh patients MRD-negative; responses durable >22 months.
- Pivotal AUGMENT-101 met primary endpoint: 23% CR/CRh in KMT2Ar acute leukemia; median duration 6.4 months.
- Full-year 2023 expense guidance reduced: R&D now $160-165M (prev $160-175M); total OpEx $225-230M (prev $225-240M).

## SEC filing metadata
- accession: 0000950170-23-058156
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017023058156/0000950170-23-058156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017023058156/sndx-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058156
- JSON: https://secwatch.observer/filing/0000950170-23-058156.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058156.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023058156/0000950170-23-058156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.